<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883688</url>
  </required_header>
  <id_info>
    <org_study_id>CERN08-01</org_study_id>
    <secondary_id>NCI-2012-02129</secondary_id>
    <nct_id>NCT00883688</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma</brief_title>
  <official_title>A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CERN Foundation - Collaborative Ependymoma Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of Avastin&#xD;
      (bevacizumab) and Tykerb (lapatinib) can help to control ependymoma in pediatric patients.&#xD;
      The safety of this drug combination will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Bevacizumab is designed to block the growth of blood vessels that supply nutrients necessary&#xD;
      for tumor growth. This may prevent and/or slow down the growth of cancer cells.&#xD;
&#xD;
      Lapatinib is designed to prevent or slow down the growth of cancer cells by blocking proteins&#xD;
      inside the cancer cells.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will receive bevacizumab&#xD;
      every 2 weeks while you are on study (2 times during each 4-week &quot;study cycle&quot;). The first&#xD;
      time you receive the drug, it will be given by vein over 90 minutes. If this dose is well&#xD;
      tolerated, you may receive future doses over 30 minutes.&#xD;
&#xD;
      You will take pills of lapatinib 2 times each day while you are on study. The pills should be&#xD;
      taken at about the same time each day. You should not eat or drink anything except water for&#xD;
      1 hour before or 1 hour after you take the pills. If you miss a dose, do not take extra pills&#xD;
      the next day to try and make up for the missed dose. You should report any missed pills or&#xD;
      any trouble you may have with taking the pills to your study doctor.&#xD;
&#xD;
      You will be given a patient diary in which you must record what time you take lapatinib each&#xD;
      time.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At all study visits, you will be asked about any other drugs that you may be taking and about&#xD;
      any side effects that you may be experiencing.&#xD;
&#xD;
      During Cycle 1 the following tests and procedures will be performed at least 1 time each&#xD;
      week:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
      Two (2) times each week during Cycle 1, blood (about 2-3 teaspoons) will be drawn for routine&#xD;
      tests.&#xD;
&#xD;
      At the end of Cycle 1, urine will be collected for routine tests.&#xD;
&#xD;
      On Days 1 and 15 of Cycle 2, the following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) will be drawn for routine tests.&#xD;
&#xD;
      At the end of Cycle 2, you will have an MRI scan of your head to check the status of the&#xD;
      disease. If your doctor thinks it is needed, you will also have an MRI of your spine and a&#xD;
      spinal tap to check your cerebrospinal fluid (CSF) for presence of disease.&#xD;
&#xD;
      On Day 1 of Cycle 3 and beyond, the following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) and urine will be collected for routine tests.&#xD;
&#xD;
      Every 8 weeks, starting with the end of Cycle 4, while you are on study, the following tests&#xD;
      and procedures will be performed:&#xD;
&#xD;
        -  You will have an MRI scan of the brain to check the status of the disease.&#xD;
&#xD;
        -  If your doctor thinks it is needed, you will have an MRI scan of the spine to check the&#xD;
           status of the disease.&#xD;
&#xD;
        -  If your doctor thinks it is needed, you will have a spinal tap to check your CSF for the&#xD;
           presence of disease.&#xD;
&#xD;
      Every 12 weeks while you are on study, the following tests and procedures will be performed&#xD;
      to check for possible side effects:&#xD;
&#xD;
        -  You will have an echocardiogram or a multiple gated acquisition scan (MUGA) (if the&#xD;
           study doctor thinks it is necessary) to test your heart function.&#xD;
&#xD;
        -  You will have an x-ray of your right knee.&#xD;
&#xD;
        -  If your doctor thinks it is needed, you will have an MRI scan of both knees.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be on study for up to 2 years. You will be taken off study if the disease gets&#xD;
      worse, if you experience intolerable side effects, or if the doctor thinks it is in your best&#xD;
      interest.&#xD;
&#xD;
      End-of-Treatment Visit:&#xD;
&#xD;
      After you have finished receiving the study drugs, the following tests and procedures will be&#xD;
      performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  You will be asked about any other drugs that you may be taking and about any side&#xD;
           effects that you may be experiencing.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) will be collected for routine tests.&#xD;
&#xD;
        -  You will have an echocardiogram or a MUGA scan (if the study doctor thinks it is&#xD;
           necessary) to test your heart function.&#xD;
&#xD;
        -  You will have an x-ray of your right knee.&#xD;
&#xD;
        -  You will have MRI scans of the brain and spine to check the status of the disease.&#xD;
&#xD;
        -  If your doctor thinks it is needed, you will have a spinal tap to check the status of&#xD;
           the disease.&#xD;
&#xD;
      Long-Term Follow-up:&#xD;
&#xD;
      You will have a follow-up visit 30 days after you have finished receiving the study drugs.&#xD;
      The following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  You will be asked about any other drugs that you may be taking and about any side&#xD;
           effects that you may be experiencing.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 2-3 teaspoons) will be collected for routine tests.&#xD;
&#xD;
      This is an investigational study. Bevacizumab is FDA approved and commercially available for&#xD;
      the treatment of colon, rectum, lung and certain types of breast cancer. Lapatinib is FDA&#xD;
      approved and commercially available for the treatment of certain types of breast cancer. The&#xD;
      use of this drug combination in ependymomas in pediatric patients is investigational.&#xD;
&#xD;
      Up to 40 patients will take part in this multicenter study. Up to 6 patients will be enrolled&#xD;
      at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>4 weeks following treatment, repeat assessments up to one year.</time_frame>
    <description>Objective response rate defined as number of participants out of total participants with complete response plus partial response (CR+PR) sustained for at least four weeks. Complete Response (CR) - Complete disappearance on magnetic resonance imaging (MRI) of all enhancing tumor and mass effect, on a stable or decreasing dose of corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination and must be sustained for at least 4 weeks. If cerebrospinal fluid (CSF) for presence of disease was positive it must become negative. Partial Response (PR) - Greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of corticosteroids, accompanied by stable or improving neurological examination and must be sustained for at least 4 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Pediatric Cancers</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week &quot;study cycle&quot;). Lapatinib Pills of 700 mg/m^2/dose given orally 2 times each day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week &quot;study cycle&quot;).</description>
    <arm_group_label>Bevacizumab + Lapatinib</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Pills of 700 mg/m^2/dose given orally 2 times each day.</description>
    <arm_group_label>Bevacizumab + Lapatinib</arm_group_label>
    <other_name>Tykerb</other_name>
    <other_name>GW572016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: Patient must be &lt; or = 21 years of age.&#xD;
&#xD;
          2. Tumor: Patients must have recurrent or refractory intracranial ependymoma (including&#xD;
             myxopapillary, clear cell, papillary, tanycytic, and anaplastic ependymoma) or&#xD;
             subependymoma. Patients with primary diagnosis of intracranial ependymoma with spinal&#xD;
             cord metastases or relapse are eligible. The diagnosis must be confirmed by the CERN&#xD;
             enrolling site's pathologist on tissue from either the initial presentation or time of&#xD;
             recurrence prior to registration. For central pathology review and trial biological&#xD;
             studies, submission of a paraffin block with tumor measuring at least 1 cm x 1 cm in&#xD;
             area is preferred, but 15 x 5micro m unstained sections on slides may be provided by&#xD;
             the referring laboratory instead. Tissue must be submitted within 60 days after&#xD;
             enrollment for central processing and analysis.&#xD;
&#xD;
          3. Patients must have measureable disease which is defined as at least one measurable&#xD;
             lesion that can be accurately measured in 2 planes. Diffuse leptomeningeal involvement&#xD;
             (&quot;sugar coating&quot;) that does not allow measurement of at least one lesion in 2 planes&#xD;
             will not be considered measurable disease.&#xD;
&#xD;
          4. Patients may have had any number of prior treatment regimens (including biologic)&#xD;
             before or after radiotherapy. Patients may not have previously been treated with&#xD;
             Bevacizumab or Lapatinib. Gliadel wafers must be approved by CERN PI (Project Leader,&#xD;
             Co-Leader and Protocol PI).&#xD;
&#xD;
          5. Neurological Deficits: Patients with neurological deficits should have deficits that&#xD;
             are stable or improving for a minimum of 1 week prior to registration.&#xD;
&#xD;
          6. Performance Score: Karnofsky Performance Scale (KPS for &gt; 16 years of age) or Lansky&#xD;
             Performance Score (LPS for &lt; or = 16 years of age) &gt; or = 50 assessed within 2 weeks&#xD;
             prior to registration.&#xD;
&#xD;
          7. Evidence of recovery from any prior chemotherapy. No myelosuppressive anticancer&#xD;
             chemotherapy or biological therapy within 3 weeks (6 weeks if a nitrosourea or&#xD;
             mitomycin C agent) prior to registration.&#xD;
&#xD;
          8. Prior/Concurrent Therapy: external beam radiation therapy (XRT): Patients must have&#xD;
             had prior radiation therapy for treatment of their ependymoma. XRT must be &gt; or = 3&#xD;
             months prior to registration for craniospinal irradiation (&gt; or = 18 Gy); &gt; or = 4&#xD;
             weeks for local radiation to primary tumor; and &gt; or = 2 weeks prior to registration&#xD;
             for focal irradiation to symptomatic metastatic sites.&#xD;
&#xD;
          9. Prior/Concurrent Therapy: Bone Marrow Transplant: &gt; or = 3 months prior to&#xD;
             registration for autologous bone marrow/stem cell transplant.&#xD;
&#xD;
         10. Prior/Concurrent Therapy: Anti-convulsants: Patients with seizure disorder may be&#xD;
             enrolled if well controlled. Patients receiving enzyme-inducing anticonvulsants are&#xD;
             not eligible for this study. Patients must be off EIACD for at least 2 weeks prior to&#xD;
             registration.&#xD;
&#xD;
         11. Prior/Concurrent Therapy: Corticosteroids: Patients who are receiving corticosteroids&#xD;
             must be on a stable or decreasing dose for at least 1 week prior to registration.&#xD;
&#xD;
         12. Prior/Concurrent Therapy: Growth Factors: Off all colony forming growth factor(s) &gt; or&#xD;
             = 2 weeks prior to registration (G-CSF, GM-CSF, Erythropoietin).&#xD;
&#xD;
         13. Patients must not have received: cytochrome P450 3A4 (CYP3A4) inhibitors within seven&#xD;
             (7) days prior to registration on protocol and for the duration of the study. However,&#xD;
             amiodarone, another CYP3A4 inhibitor, should have been discontinued 6 months prior to&#xD;
             registration and for the duration of the study.&#xD;
&#xD;
         14. Patient must not have received: CYP3A4 inducers within fourteen (14) days prior to&#xD;
             registration and for the duration of the study.&#xD;
&#xD;
         15. Patient must not have received: Cimetidine within 48 hours prior and for the duration&#xD;
             of the study.&#xD;
&#xD;
         16. The following laboratory values must be assessed within 7 days prior to registration&#xD;
             and must be repeated if initial labs were done greater than (&gt;seven) (7) calendar days&#xD;
             prior to the start of therapy. Organ Function: Must have adequate organ function and&#xD;
             marrow function as defined by the following parameters: Bone Marrow: Absolute&#xD;
             neutrophil count &gt;or =1000microliter, Platelets &gt; or = 100,000 microliter (transfusion&#xD;
             independent), Hemoglobin &gt;or =8.0 g/dL. Renal: Serum creatinine &lt;or = 1.5 times upper&#xD;
             limit of institutional for age or glomerular filtration rate (GFR)&gt;or =&#xD;
             70ml/min/1.73m2 Hepatic: Total bilirubin &lt; or = 1.5 times upper limit of normal for&#xD;
             age: serum glutamate pyruvate transaminase (SGPT) (ALT)&lt;2.5x institutional upper limit&#xD;
             of normal for age and albumin &gt; or = 2g/dL. No overt renal, hepatic, cardiac or&#xD;
             pulmonary disease.&#xD;
&#xD;
         17. No overt renal, hepatic, cardiac or pulmonary disease.&#xD;
&#xD;
         18. Adequate cardiac function, assessed within 2 weeks prior to registration, defined as:&#xD;
             shortening fraction of &gt; or = 27% by echocardiogram, or ejection fracture (LVEF) &gt; or&#xD;
             = 50% by gated radionucleotide study.&#xD;
&#xD;
         19. Adequate pulmonary function, assessed within 2 weeks prior to registration, defined&#xD;
             as: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry &gt;&#xD;
             94% if there is clinical indication for determination.&#xD;
&#xD;
         20. Signed informed consent according to institutional guidelines must be obtained.&#xD;
&#xD;
         21. Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately and will be removed from the study.&#xD;
&#xD;
         22. Patient must begin therapy within 7 calendar days of registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients may not have previously been treated with Bevacizumab or Lapatinib.&#xD;
&#xD;
          2. Patients with any significant medical illnesses that, in the investigator's opinion,&#xD;
             cannot be adequately controlled with appropriate therapy or would compromise the&#xD;
             patient's ability to tolerate this therapy.&#xD;
&#xD;
          3. Patients with any disease that would obscure toxicity or dangerously alter drug&#xD;
             metabolism.&#xD;
&#xD;
          4. Patients receiving any other anticancer or experimental drug therapy.&#xD;
&#xD;
          5. Patients with uncontrolled infection.&#xD;
&#xD;
          6. Patients on enzyme inducing anticonvulsants.&#xD;
&#xD;
          7. Patients with &gt; / = Grade 2 uncontrolled hypertension.&#xD;
&#xD;
          8. History of a stroke, myocardial infarction, or unstable angina in the previous 6&#xD;
             months.&#xD;
&#xD;
          9. Evidence of a bleeding diathesis, coagulopathy or PT international normalized ratio&#xD;
             (INR)&gt;1.5.&#xD;
&#xD;
         10. Patients who require the use of therapeutic anti-coagulation: except as required to&#xD;
             maintain patency of preexisting permanent vascular catheter.&#xD;
&#xD;
         11. Pre-existing coagulopathy or thrombosis: Patients must not have been previously&#xD;
             diagnosed with a deep venous or arterial thrombosis (including pulmonary embolism),&#xD;
             and must not have a known thrombophilic condition.&#xD;
&#xD;
         12. Patients must have recovered from any surgical procedure before enrolling on this&#xD;
             study.&#xD;
&#xD;
         13. History of an abdominal fistula, GI perforation, or intra-abdominal abscess within&#xD;
             previous 6 months.&#xD;
&#xD;
         14. A serious, non healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         15. Evidence of a new intracranial or intratumoral hemorrhage that is larger than a&#xD;
             punctuate size on baseline MRI obtained within 14 days prior to study registration.&#xD;
&#xD;
         16. If there is proteinuria present on dipstick, patients must have a 24 hour urine&#xD;
             collection. Patients are excluded if they have &gt;500 mg protein on 24 hour urine&#xD;
             collection.&#xD;
&#xD;
         17. Pregnancy: Females of childbearing potential must have negative serum or urine&#xD;
             pregnancy test within 7 days prior to study entry. The effects of lapatinib on the&#xD;
             developing human fetus are unknown. However, bevacizumab is known to be teratogenic&#xD;
             and detrimental to fetal development and endometrial proliferation, thereby having a&#xD;
             negative effect on fertility.&#xD;
&#xD;
         18. Breastfeeding: Because there is an unknown but potential risk for adverse events in&#xD;
             nursing infants secondary to treatment of the mother with lapatinib of bevacizumab,&#xD;
             breastfeeding should be discontinued if the mother is treated on this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E. Rytting, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <results_first_submitted>April 11, 2016</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Tumor</keyword>
  <keyword>Recurrent Ependymoma</keyword>
  <keyword>Refractory Ependymoma</keyword>
  <keyword>Intracranial ependymoma</keyword>
  <keyword>Ependymoblastoma</keyword>
  <keyword>Subependymoma</keyword>
  <keyword>Myxopapillary</keyword>
  <keyword>Clear cell</keyword>
  <keyword>Anaplastic</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Anti-VEGF Monoclonal Antibody</keyword>
  <keyword>rhuMAb-VEGF</keyword>
  <keyword>Lapatinib</keyword>
  <keyword>Tykerb</keyword>
  <keyword>GW572016</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: July 23, 2009 to April 3, 2013. All recruitment done in medical clinics.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Lapatinib</title>
          <description>Bevacizumab 10 mg/kg intravenous over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week &quot;study cycle&quot;). Lapatinib 700 mg/m^2/dose given orally 2 times each day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Lapatinib</title>
          <description>Bevacizumab 10 mg/kg intravenous over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week &quot;study cycle&quot;). Lapatinib 700 mg/m^2/dose given orally 2 times each day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate</title>
        <description>Objective response rate defined as number of participants out of total participants with complete response plus partial response (CR+PR) sustained for at least four weeks. Complete Response (CR) - Complete disappearance on magnetic resonance imaging (MRI) of all enhancing tumor and mass effect, on a stable or decreasing dose of corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination and must be sustained for at least 4 weeks. If cerebrospinal fluid (CSF) for presence of disease was positive it must become negative. Partial Response (PR) - Greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of corticosteroids, accompanied by stable or improving neurological examination and must be sustained for at least 4 weeks.</description>
        <time_frame>4 weeks following treatment, repeat assessments up to one year.</time_frame>
        <population>Of the total, 22 participants were eligible and only 20 evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Lapatinib</title>
            <description>Bevacizumab 10 mg/kg intravenous over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week &quot;study cycle&quot;). Lapatinib 700 mg/m^2/dose given orally 2 times each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective response rate defined as number of participants out of total participants with complete response plus partial response (CR+PR) sustained for at least four weeks. Complete Response (CR) - Complete disappearance on magnetic resonance imaging (MRI) of all enhancing tumor and mass effect, on a stable or decreasing dose of corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination and must be sustained for at least 4 weeks. If cerebrospinal fluid (CSF) for presence of disease was positive it must become negative. Partial Response (PR) - Greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of corticosteroids, accompanied by stable or improving neurological examination and must be sustained for at least 4 weeks.</description>
          <population>Of the total, 22 participants were eligible and only 20 evaluable for response.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection through 8 week treatment and may continue for up to 26 courses (2 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Lapatinib</title>
          <description>Bevacizumab 10 mg/kg intravenous over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week &quot;study cycle&quot;). Lapatinib 700 mg/m^2/dose given orally 2 times each day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection (ANC &lt;1.0 x 10^9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdomen Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestional Obstruction: Gallbladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increase serum glutamic pyruvic transaminase (ALT, SGPT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Increase serum glutamic oxaloacetic transaminase (AST, SGOT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Increase creatine phosphokinase (CPK )</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>High gamma-Glutamyl transpeptidase (GGT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity Pain, Limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Central Nervous System</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cranial Neuropathy CN IX Motor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage: Respiratory tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pustular Rash/Scalp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection (ANC &lt;1.0 x 10^9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Platelets low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hearing: patients with/without baseline audiogram and enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Otitis, external ear (non-infectious)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : External ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid appearance (e.g., moon face, buffalo hump, centripetal obesity, cutaneous striae)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ptosis, dry eyes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia/diplopia (double vision)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="44" subjects_affected="18" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Blood in stool, gas)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) : Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic) : Oral cavity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Abdomen NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Stomach</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <description>Changes in appearance, voice, appetite</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>In absence of neutropenia, where neutropenia defined as ANC &lt;1.0 x 10^9/L</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, GI : Gallbladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy - Bumpy tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, Upper Respiratory)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Grade 1/2 neutrophils</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection normal ANC or Grade 1 or 2 neutrophils: Foreign body</sub_title>
                <description>Foreign body (e.g., graft, implant, prosthesis, stent)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Trachea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC : Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC : Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Coagulation: Activated partial thromboplastin time (aPTT or APTT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase) increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Creatinine Increases</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemoglobin Change</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, phosphorus increase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Prolonged intubation after pulmonary resection (&gt;24 hrs after surgery)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Partial Thromboplastin Time (PTT) outside normal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spine-range of motion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Extremity-lower</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Left-sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Right-sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weakness, limp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Knee Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain - Thigh</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Back</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Extremity-limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Muscle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Laryngeal nerve dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Central Nervous System (CNS) affectation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cranial Neuropathy: CN IX Motor-pharynx</sub_title>
                <description>Sensory-ear, pharynx, tongue</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cranial Neuropathy: CN VI Lateral deviation of eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cranial Neuropathy: CN VII Motor-face</sub_title>
                <description>Sensory-taste</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cranial Neuropathy: CN X Motor-palate</sub_title>
                <description>pharynx, larynx</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cranial Neuropathy: CN XII Motor-tongue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Motor Neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Head/headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mood alteration : Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mood alteration : Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (urination issues)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory : Nose</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory : Respiratory tract NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain : Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory arrest/choking, congestion, tachypnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sores &amp; pustules</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Striae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other (Specify, swollen hands)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>MD Anderson Multicenter coordinating for Collaborative Ependymoma Research Network Study (CERN)</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

